4.6 Article

Restoring HOXD10 Exhibits Therapeutic Potential for Ameliorating Malignant Progression and 5-Fluorouracil Resistance in Colorectal Cancer

Journal

FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.771528

Keywords

colorectal cancer; HOXD10; DNA methylation; miR-7; IGFBP3; 5-fluorouracil; chemosensitivity

Categories

Funding

  1. National Natural Science Foundation of China [81672826, 81874179]
  2. Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai [2017YQ044]
  3. Shanghai Pujiang Talent Plan [18PJD047]
  4. Science and Technology Commission of Shanghai Municipality [18411969900]

Ask authors/readers for more resources

HOXD10 is frequently methylated and silenced in colorectal cancer, and its hypermethylation is associated with advanced disease and lymph node metastasis. Functionally, HOXD10 acts as a tumor suppressor gene, suppressing cell proliferation, colony formation, and migration and invasion. Mechanistically, DNMT1, DNMT3B, and MeCP2 are recruited in the HOXD10 promoter, and demethylation can induce HOXD10 expression. Restoring HOXD10 expression enhances chemosensitivity to 5-fluorouracil by upregulating miR-7 and IGFBP3, suggesting potential therapeutic relevance in colorectal cancer.
Emerging evidence suggests that hypermethylation of HOXD10 plays an important role in human cancers. However, the biological and clinical impacts of HOXD10 overmethylation and its downstream targets in colorectal cancer remain unknown. We evaluated the methylation level of HOXD10 in paired cancer and normal tissues (n = 42) by using pyrosequencing, followed by validation of the methylation status of HOXD10 from The Cancer Genome Atlas (TCGA) datasets with 302 cancer tissues and 38 normal tissues. The biological function of HOXD10 was characterized in cell lines. We further evaluated the effects of HOXD10 and its targets on chemoresistance in our established resistant cell lines and clinical cohort (n = 66). HOXD10 was found frequently methylated in colorectal cancer, and its hypermethylation correlates with its low expression level, advanced disease, and lymph node metastasis. Functionally, HOXD10 acts as a tumor suppressor gene, in which HOXD10-expressing cells showed suppressed cell proliferation, colony formation ability, and migration and invasion capacity. Mechanistically, DNMT1, DNMT3B, and MeCP2 were recruited in the HOXD10 promoter, and demethylation by 5-Aza-2 '-deoxycytidine (5-Aza-CdR) treatment or MeCP2 knockdown can sufficiently induce HOXD10 expression. HOXD10 regulates the expressions of miR-7 and IGFBP3 in a promoter-dependent manner. Restoration of the expression of HOXD10 in 5-fluorouracil (5-FU)-resistant cells significantly upregulates the expressions of miR-7 and IGFBP3 and enhances chemosensitivity to 5-FU. In conclusion, we provide novel evidence that HOXD10 is frequently methylated, silenced, and contributes to the development of colorectal cancers. Restoration of HOXD10 activates the expressions of miR-7 and IGFBP3 and results in an inhibited phenotype biologically, suggesting its potential therapeutic relevance in colorectal cancer (CRC).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available